Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMAT - ultrafast tomography for coronary artery disease -- Ignore unavailable to you. Want to Upgrade?

To: Silver Knife who wrote (2944)	3/7/1999 11:47:00 PM
From: dwight martin	Respond to of 3725

I wish you would repost, addressing each study with a short comment. To me, the studies either reconfirm or presuppose the worth of EBCT, esp. as compared to angiography (EBCT-derived CAC score confirmed existing disease better than angiogram). TIA

To: Silver Knife who wrote (2944)	3/7/1999 11:53:00 PM
From: Angel Medina	Read Replies (1) \| Respond to of 3725

Good show Bernie. Articles like these would have sent Imat through the roof four years ago. Today's potential stock buyers have heard the same story too many times. Its like a joke: you can only tell the same joke so many times before it stops being funny. My loss on this "crap" approaches six figures, that is why I can not sell and feel good about it, but I have agonized so much with it that I have little hope, but lots of wishful thinking.